⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180823 | 0.97 | — | — | |
| SCHEMBL31290754 | 0.97 | MGAM (0.58) | — | |
| SCHEMBL29002113 | 0.94 | MGAM (0.55) | — | |
| SCHEMBL28356244 | 0.94 | — | — | |
| Rubidium SCHEMBL3181136 | 0.94 | — | — | |
| SCHEMBL25276833 | 0.94 | — | — | |
| SCHEMBL2846065 | 0.94 | — | — | |
| SCHEMBL3181134 | 0.94 | — | — | |
| SCHEMBL3197986 | 0.94 | — | — | |
| Malonic Acid SCHEMBL4212077 | 0.94 | LDHA (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115207-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3962921-B1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12337004-B2 | Coumarin-modified androgens for the treatment of prostate cancer | HEALTH RESEARCH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20220218722-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-07-14 | — | — | US | disclosed |
| WO-2020223174-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10632191-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3124491-B1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS AND VACCINE COMPOSITIONS AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | INFECTIOUS DISEASE RES INST (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2018-02-01 | — | — | US | disclosed |
| US-9814772-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| CN-101006092-A | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and therapeutic agents using the same | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1781662-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007023381-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| CN-1849121-A | Piperazine derivatives as bradyknin antagonist | AMGEN INC (US) | 2006-10-18 | — | — | CN | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-5189043-A | Useful as an inhibitory agent for the biosynthesis of cholesterol | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0424929-A1 | Isoquinolone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-05-02 | — | — | EP | disclosed |